It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Borderline personality disorder (BPD) is a severe and highly prevalent psychiatric disorder, more common in females than in males and with notable differences in presentation between genders. Recent studies have shown that epigenetic modifications such as DNA methylation may modulate gene × environment interactions and impact on neurodevelopment. We conducted an epigenome wide study (Illumina Infinium HumanMethylation450k beadchip) in a group of BPD patients with (N = 49) and without (N = 47) childhood traumas and in a control group (N = 44). Results were confirmed in a replication cohort (N = 293 BPD patients and N = 114 controls) using EpiTYPER assays. Differentially methylated CpG sites were observed in several genes and intragenic regions in the X chromosome (PQBP1, ZNF41, RPL10, cg07810091 and cg24395855) and in chromosome 6 (TAP2). BPD patients showed significantly lower methylation levels in these CpG sites than healthy controls. These differences seemed to be increased by the existence of childhood trauma. Comparisons between BPD patients with childhood trauma and patients and controls without revealed significant differences in four genes (POU5F1, GGT6, TNFRSF13C and FAM113B), none of them in the X chromosome. Gene set enrichment analyses revealed that epigenetic alterations were more frequently found in genes controlling oestrogen regulation, neurogenesis and cell differentiation. These results suggest that epigenetic alterations in the X chromosome and oestrogen-regulation genes may contribute to the development of BPD and explain the differences in presentation between genders. Furthermore, childhood trauma events may modulate the magnitude of the epigenetic alterations contributing to BPD.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Fundació Docència i Recerca Mutua Terrassa, Terrassa, Spain (GRID:grid.414875.b) (ISNI:0000 0004 1794 4956); Institut de Recerca Biomèdica Sant Pau (IIB-Sant Pau), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (GRID:grid.7722.0) (ISNI:0000 0001 1811 6966)
2 Fundació Docència i Recerca Mutua Terrassa, Terrassa, Spain (GRID:grid.414875.b) (ISNI:0000 0004 1794 4956); Institut de Recerca Biomèdica Sant Pau (IIB-Sant Pau), Stroke Pharmacogenomics and Genetics Group, Barcelona, Spain (GRID:grid.7722.0) (ISNI:0000 0001 1811 6966)
3 Institut de Recerca Biomèdica Sant Pau (IIB-Sant Pau), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (GRID:grid.7722.0) (ISNI:0000 0001 1811 6966); Hospital de la Santa Creu i Sant Pau, Department of Psychiatry, Barcelona, Spain (GRID:grid.413396.a) (ISNI:0000 0004 1768 8905); Universitat Autònoma de Barcelona, Department of Psychiatry and Forensic Medicine & Institute of Neurosciences, Bellaterra, Spain (GRID:grid.7080.f)
4 Hospital de la Santa Creu i Sant Pau, Department of Psychiatry, Barcelona, Spain (GRID:grid.413396.a) (ISNI:0000 0004 1768 8905)
5 Institut de Recerca Biomèdica Sant Pau (IIB-Sant Pau), Translational Medical Oncology Laboratory, Bellaterra, Spain (GRID:grid.7722.0) (ISNI:0000 0001 1811 6966)
6 Universitat Autònoma de Barcelona, Department of Psychiatry and Forensic Medicine & Institute of Neurosciences, Bellaterra, Spain (GRID:grid.7080.f); Consorci Sanitari de l’Anoia & Fundació Sanitària d’Igualada, Psychiatry and Mental Health Department, Hospital of Igualada, Igualada, Spain (GRID:grid.7080.f)
7 Consorci Sanitari de l’Anoia & Fundació Sanitària d’Igualada, Psychiatry and Mental Health Department, Hospital of Igualada, Igualada, Spain (GRID:grid.7080.f)